The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Johnson's group demonstrated in a 2023 study that congenital syphilis is not more likely with a prenatal dose schedule using ...
4don MSN
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...
SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results